For the prediction of metastatic vs. nonmetastatic CRC, the optimum cutoff points for the explored biomarkers were set at CD45neg EpCAMpos CTCs (continuous), CD45neg EpCAMneg cells ≥ 400/7 mL and CEA > 5 ng/mL based on the data in Tables S1–S5. This evidence concerns the gene CEACAM5 and colorectal carcinoma.